Clinical trials of sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated improvement in kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) with and without diabetes.
SGLT2i in Management of Chronic Kidney Disease
Posted: Friday, September 9, 2022
Category - Medicines Update